Role of RANTES and its receptor in gastric cancer metastasis

Abstract

This study examined the role of regulated upon activation normal T cell expressed and secreted (RANTES) and its receptor C-C chemokine receptor type 5 (CCR5) in gastric cancer metastasis and the associated mechanism. The expression of RANTES and CCR5 was detected by using immunohistochemical staining and Western blotting in the gastric cancer tissues obtained from 60 gastric cancer patients with or without lymph node metastasis (n=30 in each). The results showed that the expression levels of RANTES and CCR5 were higher in gastric cancer with lymph node metastasis than in that without metastasis (P<0.05). The expression levels of RANTES in 30 lymph nodes with cancerous invasion were higher than in 30 normal lymph nodes (P<0.05). Chemotactic test revealed that the number of migrating gastric cancer cells (n=295.0±54.6) induced by the protein of cancer-invading lymph nodes was greater than that by the protein mixture from cancer-invading lymph nodes and RANTES antibody (n=42.5±11.6) (P<0.05). RT-PCR showed that the expression levels of the main Th1 cytokines (IL-2, Γ-IFN) were lower in gastric cancer with lymph node metastasis (2.22±0.90, 3.26±1.15 respectively) than in that without metastasis (3.07±1.67, 4.77±1.52 respectively) (P<0.05), but the expression level of the main Th 2 cytokine (IL-10) was higher in gastric cancer with lymph nodes metastasis (6.06±2.04) than in that without metastasis (4.88±1.87) (P<0.05). It was concluded that RANTES and its receptor CCR5 may contribute to gastric cancer metastasis through influencing the balance of Th1/Th2. RANTES and CCR5 may become a marker of gastric cancer metastasis.

Keywords

regulated upon activation normal T cell expressed and secreted / gastric cancer / metastasis / chemotaxis

References

[1] HuangZ.H., HuaD., DuX., et al.. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol, 2008, 14(41): 6401-6407

[2] HensonD.E., DittusC., YounesM., et al.. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States-2000: increase in the signet ring cell type. Arch Pathol Lab Med, 2004, 128(7): 765-770

[3] HiraoM., OnaiN., HiroishiK., et al.. CC chemokine receptor 27 on dendritic cells induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 2000, 60(8): 2209-2217

[4] GerardC., RollinsB.J.. Chemokines and disease. Nat Immunol, 2001, 2(2): 108-115

[5] Ben-BaruchA.. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev, 2006, 25(3): 357-371

[6] ZlotnikA.. Involvement of chemokine receptors in organ specific metastasis. Contrib Microbiol, 2006, 13(1): 191-199

[7] Ben-BaruchA.. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis, 2008, 25(4): 345-356

[8] MurphyP.M., BaggioliniM., CharoI.F., et al.. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev, 2000, 52(1): 145-176

[9] LuboshitsG., ShinaS., KaplanO., et al.. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res, 1999, 59(18): 4681-4687

[10] Yaal-HahoshenN., ShinaS., Leider-TrejoL., et al.. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res, 2006, 12(15): 4474-4480

[11] ZhangP., LiH., WuM.L., et al.. c-Myc downregulation: a critical molecular event in resveratrolinduced cell cycle arrest and apoptosis of human medulloblastoma cells. J Neurooncol, 2006, 80(2): 123-131

[12] JohnsonZ., Kosco-VilboisM.H., HerrenS., et al.. Interference with heparine blinding and obliogomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol, 2004, 173(9): 5776-5785

[13] SoriaG., Yaal-HahoshenN., AzenshteinE., et al.. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine, 2008, 44(1): 191-200

[14] SoriaG., Ben-BaruchA.. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett, 2008, 267(2): 271-285

[15] MüllerA., HomeyB., SotoH., et al.. Involvement of chemokine receptor in breast cancer metastasis. Nature, 2001, 410(6824): 50-56

[16] AldinucciD., LorenzonD., CattaruzzaL., et al.. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer, 2008, 122(4): 769-776

[17] EissaS.A., ZakiS.A., El-MaghrabyS.M., et al.. Important of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 2005, 17(1): 51-55

[18] StrieterR.M., BurdickM.D., MestasJ., et al.. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer, 2006, 42(6): 768-778

[19] KarnoubA.E., DashA.B., VoA.P., et al.. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007, 449(7162): 557-563

[20] VadayG.G., PeehlD.M., KadamP.A., et al.. Expression of CCL5 (RANTES) and CCR5 in prestate cancer. Prostate, 2006, 66(2): 124-134

[21] BorczukA.C., PapanikolaouN., ToonkelR.L., et al.. Lung adenocarcinoma invasion in TGF beta RII-deficient cells is mediated by CCL5/RANTES. Oncogene, 2008, 27(4): 557-564

[22] KimH.K., SongK.S., ParkY.S., et al.. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer, 2003, 39(2): 184-191

[23] SuttonA., FriandV., Papy-GarciaD., et al.. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther, 2007, 6(11): 2948-2958

[24] RobinsonS.C., ScottK.A., WilsonJ.L., et al.. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res, 2003, 63(23): 8360-8365

[25] VitielloP.F., ShainheitM.G., AllisonE.M., et al.. Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett, 2004, 91(2–3): 239-245

[26] AdlerE.P., LemkenC.A., KatchenN.S., et al.. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett, 2003, 90(2–3): 187-194

[27] Della BellaS., MolteniM., CompassoS., et al.. Differential effects of cyclooxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids, 1997, 56(3): 177-84

[28] HuangM., StolinaM., SharmaS., et al.. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin12 production. Cancer Res, 1998, 58(6): 1208-1216